Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14214 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Hans C Lee und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Boron Compounds, Glycine, Lenalidomide. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AHRQ HHS, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Abstract (Originalsprache)
Objectives
To characterize the impact of prior exposure and refractoriness to lenalidomide or proteasome inhibitors (PIs) on the effectiveness and safety of ixazomib–lenalidomide–dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM).
Methods
INSURE is a pooled analysis of adult RRMM patients who had received IRd in ≥2 line of therapy from three studies: INSIGHT MM, UVEA‐IXA, and REMIX.
Results
Overall, 391/100/68 were lenalidomide‐naïve/−exposed/−refractory and 37/411/110 were PI‐naïve/−exposed/−refractory. Median duration of therapy (DOT) was 15.3/15.6/4.7 months and median progression‐free survival (PFS) was 21.6/25.8/5.6 months in lenalidomide‐naïve/exposed/refractory patients. Median DOT and PFS in PI‐naïve/exposed/refractory patients were 20.4/15.2/6.9 months and not reached/19.8/11.4 months, respectively. The proportion of lenalidomide‐naïve/exposed/refractory patients in INSIGHT and UVEA‐IXA who discontinued a study drug due to adverse events (AEs) was ixazomib, 31.6/28.2/28.0% and 18.6/6.7/10.5%; lenalidomide, 21.9/28.2/16.0% and 16.1/6.7/10.5%; dexamethasone, 18.4/20.5/16.0% and 10.6/0/10.5%, respectively. The proportion of PI‐naïve/exposed/refractory patients in INSIGHT and UVEA‐IXA who discontinued a study drug due to AEs was: ixazomib, 44.4/28.8/27.8% and 22.2/16.7/15.7%; lenalidomide, 33.3/22.0/19.4% and 16.7/15.9/11.8%; dexamethasone, 33.3/17.4/16.7% and 16.7/9.5/7.8%, respectively. REMIX AE discontinuation rates were unavailable.
Conclusion
IRd appeared to be effective in RRMM patients in routine clinical practice regardless of prior lenalidomide or PI exposure, with better outcomes seen in lenalidomide‐ and/or PI‐nonrefractory versus refractory patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, UK.
- CHU de Caen Normandie, Caen, France.
- Perlmutter Cancer Center, NYU Langone, New York City, New York, USA.
- Indiana University School of Medicine, Indianapolis, Indiana, USA.
- University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, USA.
ORCID-Profile: Hans C Lee, Karthik Ramasamy
Förderung
- AHRQ HHS
- Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA
Zitieren
APA
Lee, H. C., Ramasamy, K., Macro, M., Davies, F. E., Abonour, R., van Rhee, F., Hungria, V. T. M., Puig, N., Ren, K., Silar, J., Enwemadu, V., Cherepanov, D., & Leleu, X. (2024). Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study. European Journal of Haematology. https://doi.org/10.1111/ejh.14214
Vancouver
Lee HC, Ramasamy K, Macro M, Davies FE, Abonour R, van Rhee F, et al. Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study. European Journal of Haematology. 2024. doi:10.1111/ejh.14214
BibTeX
@article{Lee2024,
author = {Lee, Hans C and Ramasamy, Karthik and Macro, Margaret and Davies, Faith E and Abonour, Rafat and van Rhee, Frits and Hungria, Vania T M and Puig, Noemi and Ren, Kaili and Silar, Jiri and Enwemadu, Victoria and Cherepanov, Dasha and Leleu, Xavier},
title = {Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14214}
}
EUVIMED